platoseedplatoseed
Adventris makes cancer vaccines
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
Adventris Pharmaceuticals is a biotechnology company focused on cancer immunotherapy and cancer vaccines. The site emphasizes partnerships and information inquiries for development opportunities.
The company centers on cancer immunotherapy and vaccines, pursuing partnerships for development in the oncology vaccines space. Specific product mechanisms or concrete vaccine technology details are not provided on the page.
Who it’s for: biotech/pharma partners, researchers, and potential collaborators in oncology development
Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.
William Collis is a serial entrepreneur with multiple exits, most recently the data platform Genji. His research has been published in Harvard Business review and featured as a TED talk with over 1.5M views. He holds an MBA from Harvard Business School where he was named a Baker Scholar. He is lifelong friends with his co-founders Jen Herbach and Mark Yarchoan, since meeting as roommates at Amherst College.
Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.
By teaching our body’s immune system to recognize and kill the mutations that cause cancer we can eliminate the majority of all cancer deaths.
Adventris develops cancer vaccines that train the immune system to target mutations driving cancer, starting with a lung cancer vaccine against KRAS. The company aims to treat cancer and, long term, to vaccinate adults annually to prevent many cancer deaths.
From the original launch (Jan 2023) — may be outdated.
Formerly “Elimivax” · why startups rename →
Creating new protein-based drugs at scale
Our drugs engage the immune system to fight tumors
